Pfizer and Merck KGaA’s tweaks to the Javelin Lung 100 study of their PD-L1 antibody avelumab, which will delay its readout by almost two years, look like a painful but necessary adjustment to commercial realities in this competitive cancer indication. The changes will more than double the size of the study, in first-line non-small cell lung cancer, and push data out to mid-2019.
Category: Bristol Myers Squibb
Merck 2017 forecast eases concerns over royalty payments, dollar
Merck & Co Inc reported better-than-expected U.S. quarterly sales for its key cancer drug, Keytruda, and forecast largely in-line 2017 results, which some analysts said allayed concerns over the impact of a strong dollar and royalty payments. The logo of Merck is pictured in this illustration photograph in Cardiff, California April 26, 2016.
Roche Sees Sales Boost in 2017 With New Lung Drug on U.S. Market
Roche Holding AG pointed toward rising sales this year as its new cancer immune therapy Tecentriq gains wider use for lung tumors. Revenue will probably rise by a low to mid-single digit percentage at constant exchange rates, the same pace as earnings per share excluding some items, the Basel, Switzerland-based company said in a statement Wednesday.
The Battle For Bristol-Myers Begins
Bristol-Myers has activist investor Barry Rosenstein and his JANA Partners as a shareholder. JANA hasn’t announced any plans, or even considered the stake activist.
Why Bristol-Myers Squibb Co Stock Is Slipping Today
An announcement that it won’t seek accelerated approval for a combination lung cancer therapy comprised of two key drugs isn’t sitting well with the market in light of Merck & Co. ‘s Lung cancer might not be the most common malignancy, but it is the deadliest.
Bristol-Myers Squibb stock sinks 7.2% after it says it won’t pursue…
The company said the decision was made “based on a review of the data available at this time,” and said it would say no more “in order to protect the integrity of ongoing registrational studies.” Leerink analyst Seamus Fernandez said the development was a “clear setback for BMY,” especially given a fall approval by rival drugmaker Merck in first-line lung cancer.
Bristol-Myers Falls Further Behind Merck in Lung Cancer Race
Bristol-Myers Squibb Co. fell after the drugmaker said it wouldn’t seek accelerated approval for a combination of its drugs to treat first-line lung cancer.
Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales
… revenue will propel innovation, the costs are stoking patients’ distress and creating a rift between manufacturers, health authorities and payers in many markets. Take the new lung-cancer drugs from Merck & Co., Bristol-Myers Squibb Co. and Roche …
Ono Pharma’s Wild 2016 Ride Cuts Stock Valuation by $16 Billion
… in the sector,” says Nomura’s Kohtani, who rates Ono shares neutral. The troubles were compounded by the Japan Health Ministry’s decision in November to lower Opdivo’s price by half, forcing Ono to lower its profit outlook for the current fiscal …
Doxorubicin Market 2013 – 2024 – Research and Markets
… in demand for the drug. The technological advancement in te drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal …
PTAB Upholds Validity of BMS Patent
The PTAB issued a Final Written Decision upholding the validity of Bristol-Myers Squibb’s U.S. Patent 8,476,239, which had been challenged by Momenta in IPR2015-01537. According to documents filed with the PTAB during the IPR, the ‘239 patent covers stable formulations of a protein called “CTLA4Ig.”